SCN1A and Dravet syndrome: In a different study, CRISPR/Cas9 was used to knock-in (KI) a pathogenic, PE promoting, variant of sodium channel, voltage-gated, type I, alpha (Scn1a) to generate a Dravet Syndrome (DS) mouse model (Voskobiynyk et al., 2021).